Enrichment strategy for cardiovascular clinical trials
Cardiovascular clinical trials try to demonstrate the benefit of a medication on populations where the number of participants with the targeted disease is very low. The low efficacy of treatment is partially due to the diversity of diseases and of the population. To improve the efficacy of treatment, it is necessary to improve the recruitment of participants that are at greater risk of the studied disease through a process known as “population enrichment”. This project proposes the development of a tool for population enrichment by identifying participants at greater risk of a cardiovascular event based on laboratory blood work, clinical data, and specific genetic mutations. This will allow further identification of subgroups most likely to benefit from cardiovascular treatment. Ultimately, this technology could become a stepping stone for the use of precision medicine in cardiovascular diseases.